Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Glutarate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC11 known ✓ | Q96DB2 | 3/20 | 0.59 |
| ▸ | GABRP known ✓ | O00591 | 1/20 | 0.59 |
| ▸ | GABRD known ✓ | O14764 | 1/20 | 0.59 |
| ▸ | HDAC3 known ✓ | O15379 | 1/20 | 0.59 |
| ▸ | GABRA1 known ✓ | P14867 | 1/20 | 0.59 |
| ▸ | GABRB1 known ✓ | P18505 | 1/20 | 0.59 |
| ▸ | GABRG2 known ✓ | P18507 | 1/20 | 0.59 |
| ▸ | GABRB3 known ✓ | P28472 | 1/20 | 0.59 |
| ▸ | SLC6A1 known ✓ | P30531 | 1/20 | 0.59 |
| ▸ | GABRA5 known ✓ | P31644 | 1/20 | 0.59 |
| ▸ | GABRA3 known ✓ | P34903 | 1/20 | 0.59 |
| ▸ | GABRA2 known ✓ | P47869 | 1/20 | 0.59 |
| ▸ | GABRB2 known ✓ | P47870 | 1/20 | 0.59 |
| ▸ | GABRA4 known ✓ | P48169 | 1/20 | 0.59 |
| ▸ | HDAC4 known ✓ | P56524 | 1/20 | 0.59 |
| ▸ | GABRE known ✓ | P78334 | 1/20 | 0.59 |
| ▸ | HDAC1 known ✓ | Q13547 | 1/20 | 0.59 |
| ▸ | GABRA6 known ✓ | Q16445 | 1/20 | 0.59 |
| ▸ | GABRG1 known ✓ | Q8N1C3 | 1/20 | 0.59 |
| ▸ | HDAC7 known ✓ | Q8WUI4 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glutarate SCHEMBL237796 | 1.00 | SLC22A6 (0.92) | SLC22A6LMNATSHRNFKB1PMP22 | |
| Glutarate SCHEMBL10696094 | 0.96 | SLC22A6 (0.85) | SLC22A6LMNATSHRNFKB1PMP22 | |
| Glutarate SCHEMBL11625209 | 0.96 | SLC22A6 (0.85) | SLC22A6LMNATSHRNFKB1PMP22 | |
| Glutarate SCHEMBL27893539 | 0.96 | SLC22A6 (0.85) | SLC22A6LMNATSHRNFKB1PMP22 | |
| Glutarate SCHEMBL29160998 | 0.96 | SLC22A6 (0.85) | SLC22A6LMNATSHRNFKB1PMP22 | |
| Glutarate SCHEMBL27601182 | 0.96 | SLC22A6 (1.00) | SLC22A6LMNATSHRNFKB1PMP22 | |
| Glutarate SCHEMBL158774 | 0.96 | SLC22A6 (1.00) | SLC22A6LMNATSHRNFKB1PMP22 | |
| Glutarate SCHEMBL7414 | 0.96 | — | — | |
| Glutarate SCHEMBL6701735 | 0.96 | — | — | |
| Glutarate SCHEMBL11453117 | 0.92 | SLC22A6 (0.92) | SLC22A6LMNATSHRNFKB1PMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612364-B2 | Salts and solid forms of 4-hydroxy-N,N-diisopropyltryptamine hemi-glutarate and hemi-succinate | TERRAN BIOSCIENCES INC. (US) | 2026-04-28 | — | — | US | claimed |
| US-20260085041-A1 | SALTS AND SOLID FORMS OF 4-HYDROXY-N,N-DIISOPROPYLTRYPTAMINE HEMI-GLUTARATE AND HEMI-SUCCINATE | TERRAN BIOSCIENCES INC (US) | 2026-03-26 | — | — | US | claimed |
| US-20250066299-A1 | SALTS AND SOLID FORMS OF 4-HYDROXY-N,N-DIISOPROPYLTRYPTAMINE HEMI-GLUTARATE AND HEMI-SUCCINATE | TERRAN BIOSCIENCES INC (US) | 2025-02-27 | — | — | US | claimed |
| WO-2023133477-A1 | SALTS AND SOLID FORMS OF 4-HYDROXY-N,N-DIISOPROPYLTRYPTAMINE HEMI-GLUTARATE AND HEMI-SUCCINATE | TERRAN BIOSCIENCES, INC. (US) | 2023-07-13 | — | — | WO | claimed |
| CN-111961426-A | Joint filling sealing material, preparation method and application thereof | 嘉兴市爵拓科技有限公司 | 2020-11-20 | — | — | CN | claimed |
| US-12612364-B2 | Salts and solid forms of 4-hydroxy-N,N-diisopropyltryptamine hemi-glutarate and hemi-succinate | TERRAN BIOSCIENCES INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-12612364-B2 | Salts and solid forms of 4-hydroxy-N,N-diisopropyltryptamine hemi-glutarate and hemi-succinate | TERRAN BIOSCIENCES INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-20260085041-A1 | SALTS AND SOLID FORMS OF 4-HYDROXY-N,N-DIISOPROPYLTRYPTAMINE HEMI-GLUTARATE AND HEMI-SUCCINATE | TERRAN BIOSCIENCES INC (US) | 2026-03-26 | — | — | US | disclosed |
| US-20260085041-A1 | SALTS AND SOLID FORMS OF 4-HYDROXY-N,N-DIISOPROPYLTRYPTAMINE HEMI-GLUTARATE AND HEMI-SUCCINATE | TERRAN BIOSCIENCES INC (US) | 2026-03-26 | — | — | US | disclosed |
| US-20250066299-A1 | SALTS AND SOLID FORMS OF 4-HYDROXY-N,N-DIISOPROPYLTRYPTAMINE HEMI-GLUTARATE AND HEMI-SUCCINATE | TERRAN BIOSCIENCES INC (US) | 2025-02-27 | — | — | US | disclosed |
| US-20250066299-A1 | SALTS AND SOLID FORMS OF 4-HYDROXY-N,N-DIISOPROPYLTRYPTAMINE HEMI-GLUTARATE AND HEMI-SUCCINATE | TERRAN BIOSCIENCES INC (US) | 2025-02-27 | — | — | US | disclosed |
| CN-114035342-B | Resin lens for correcting color vision | 江苏视科新材料股份有限公司 | 2024-11-01 | — | — | CN | disclosed |
| US-4565798-A | COORDINATION CATALYSTS, TITANIUM, MAGNESIUM, SILICON COMPOUND | TOA NENRYO KOGYO KABUSHIKI KAISHA (JP) | 1986-01-21 | — | — | US | disclosed |
| EP-0157472-A1 | Process for polymerization of olefins | TOA NENRYO KOGYO KABUSHIKI KAISHA (JP) | 1985-10-09 | — | — | EP | disclosed |
| EP-0156512-A1 | Process for preparing catalyst component for polymerization of olefins | TOA NENRYO KOGYO KABUSHIKI KAISHA (JP) | 1985-10-02 | — | — | EP | disclosed |
| EP-0147053-A1 | A catalyst and a process for polymerization of olefins | Tonen Corporation (JP) | 1985-07-03 | — | — | EP | disclosed |
| EP-0145368-A2 | Process for producing propylene block copolymers | TOA NENRYO KOGYO KABUSHIKI KAISHA (JP) | 1985-06-19 | — | — | EP | disclosed |
| US-4194931-A | Soldering flux | WESTERN ELECTRIC CO. (US) | 1980-03-25 | — | — | US | disclosed |
| US-4168996-A | Soldering flux | WESTERN ELECTRIC COMPANY, INC. (US) | 1979-09-25 | — | — | US | disclosed |
| US-3996292-A | Process for the preparation of aliphatic dialdehydes | RHONE-POULENC S.A. (FR) | 1976-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612364-B2 | Salts and solid forms of 4-hydroxy-N,N-diisopropyltryptamine hemi-glutarate and hemi-succinate | SLC6A4, DLST, GRIN2D | HDAC11 1414/4885GABRP 342/4885GABRD 495/4885 |
| US-20260085041-A1 | SALTS AND SOLID FORMS OF 4-HYDROXY-N,N-DIISOPROPYLTRYPTAMINE HEMI-GLUTARATE AND HEMI-SUCCINATE | SLC6A4, DLST, GRIN2D | HDAC11 1414/4885GABRP 342/4885GABRD 495/4885 |
| US-20250066299-A1 | SALTS AND SOLID FORMS OF 4-HYDROXY-N,N-DIISOPROPYLTRYPTAMINE HEMI-GLUTARATE AND HEMI-SUCCINATE | SLC6A4, SLC6A3, SLC6A2 | HDAC11 1738/4885GABRP 263/4885GABRD 324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.